Vascular Impact of Cancer Therapies: The Case ... - CLL Support
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
You need to be a member of this community to see this post.
7 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
August 16, 2020
Fewer off-target effects mean second-generation BTK inhibitors offer less...
A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor
How does zanubrutinib differ from ibrutinib in pharmacokinetics and target occupancy?
Zanubrutinib...
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial
A new BTK inhibitor enters the fray in Chronic Lymphocytic Leukaemia and Small Lymphocytic...
Clemastine (Tavegyl), an over-the-counter drug, found to be effective at inducing LMP and cell death
For what it may be worth, thougbt some of you might like to see this:
"Lysosomes in chronic...
Related Posts
1.5 million atrial fibrillation cases may be undiagnosed in US (prevalence estimate of 11%)
Ibrutinib, Acalabrutinib, or Zanubrutinib 
How Ibrutinib works over time
Alterations of the immune system caused by CLL B‐cells - UK NICE Approves Ibrutinib +Venetoclax for First Line treatment for ALL Patients from today
